CLINICAL TRIALS PROFILE FOR INFLUENZA VACCINE LIVE INTRANASAL
✉ Email this page to a colleague
All Clinical Trials for influenza vaccine live intranasal
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT01591473 ↗ | Safety Study of FluMist With and Without Ampligen | Terminated | AIM ImmunoTech Inc. | Phase 1/Phase 2 | 2012-04-01 | The purpose of this study is to evaluate FluMist with and without Ampligen in healthy volunteers. |
| NCT01591473 ↗ | Safety Study of FluMist With and Without Ampligen | Terminated | Hemispherx Biopharma | Phase 1/Phase 2 | 2012-04-01 | The purpose of this study is to evaluate FluMist with and without Ampligen in healthy volunteers. |
| NCT01866540 ↗ | Immune Response To Intranasal Influenza Vaccination | Active, not recruiting | Haukeland University Hospital | N/A | 2012-10-01 | This research during the last decade has focused on the kinetics of the systemic and local immune response to parenteral influenza vaccine in humans. The investigators have shown that normally high numbers of influenza specific antibody secreting cells (ASC) are present in the nasal mucosa of healthy adults but upon parenteral vaccination the numbers remain stable. However, a rapid transient increase in specific ASC is observed in the tonsils and peripheral blood after parenteral vaccination. In the tonsils, this is associated with a significant decrease in both naïve/effector (CD45RA+) and memory (CD45RO+) CD4+ cells upon vaccination. In this study the investigators will extend our work to investigate the characteristics of influenza-specific T- and B-cells induced locally and systemically after intranasal vaccination in man. |
| NCT01866540 ↗ | Immune Response To Intranasal Influenza Vaccination | Active, not recruiting | University of Bergen | N/A | 2012-10-01 | This research during the last decade has focused on the kinetics of the systemic and local immune response to parenteral influenza vaccine in humans. The investigators have shown that normally high numbers of influenza specific antibody secreting cells (ASC) are present in the nasal mucosa of healthy adults but upon parenteral vaccination the numbers remain stable. However, a rapid transient increase in specific ASC is observed in the tonsils and peripheral blood after parenteral vaccination. In the tonsils, this is associated with a significant decrease in both naïve/effector (CD45RA+) and memory (CD45RO+) CD4+ cells upon vaccination. In this study the investigators will extend our work to investigate the characteristics of influenza-specific T- and B-cells induced locally and systemically after intranasal vaccination in man. |
| NCT02111512 ↗ | Safety of Nasal Influenza Immunisation in Egg Allergic Children - The SNIFFLE 2 Study | Completed | Imperial College London | Phase 4 | 2014-09-01 | Egg allergy is common in early childhood, affecting at least one in 50 preschool children. Influenza ("'flu") vaccines contain egg protein, as the vaccine is cultured in hen's eggs. There is robust data to support the safety of influenza vaccines (containing low or negligible amounts of egg protein) in patients with egg allergy. A new influenza vaccine, known as LAIV (Live Attenuated Intranasal Vaccine) has recently been approved by a number of licensing boards and is given by a spray into the nose. This new vaccine has been available in the United States for several years and is highly effective and against influenza infection, with an excellent safety profile in children without egg allergy. However, LAIV is also grown in hen's eggs and contains egg protein, and there are NO published data on the safety of LAIV in egg-allergic children. In SNIFFLE 1 Study, 433 doses were given to 282 egg-allergic children; data is currently being analysed. The objective of this multicentre study is to further assess the safety of intranasal LAIV in egg-allergic children, in order to demonstrate that these children can safely be given the new LAIV within a primary care health environment. |
| NCT02111512 ↗ | Safety of Nasal Influenza Immunisation in Egg Allergic Children - The SNIFFLE 2 Study | Completed | Public Health England | Phase 4 | 2014-09-01 | Egg allergy is common in early childhood, affecting at least one in 50 preschool children. Influenza ("'flu") vaccines contain egg protein, as the vaccine is cultured in hen's eggs. There is robust data to support the safety of influenza vaccines (containing low or negligible amounts of egg protein) in patients with egg allergy. A new influenza vaccine, known as LAIV (Live Attenuated Intranasal Vaccine) has recently been approved by a number of licensing boards and is given by a spray into the nose. This new vaccine has been available in the United States for several years and is highly effective and against influenza infection, with an excellent safety profile in children without egg allergy. However, LAIV is also grown in hen's eggs and contains egg protein, and there are NO published data on the safety of LAIV in egg-allergic children. In SNIFFLE 1 Study, 433 doses were given to 282 egg-allergic children; data is currently being analysed. The objective of this multicentre study is to further assess the safety of intranasal LAIV in egg-allergic children, in order to demonstrate that these children can safely be given the new LAIV within a primary care health environment. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for influenza vaccine live intranasal
Condition Name
Clinical Trial Locations for influenza vaccine live intranasal
Trials by Country
Clinical Trial Progress for influenza vaccine live intranasal
Clinical Trial Phase
Clinical Trial Sponsors for influenza vaccine live intranasal
Sponsor Name
